Management

Gerben Moolhuizen
Gerben Moolhuizen, Chief Executive Officer

Gerben Moolhuizen has over twenty years of experience in the pharmaceutical and biotechnology industry in various roles covering business development, product development and general management. From January 2016 to May 2018, Gerben Moolhuizen served as ISA Pharmaceuticals´ Chief Business Officer (CBO) and has been promoted Chief Executive Officer effective June 1, 2018. Prior to ISA Pharmaceuticals, he worked at OctoPlus, where his most recent role was General Manager. He has been closely involved in the company´s fundraising activities, IPO, and the acquisition by Dr. Reddy’s and has also been responsible for the subsequent integration of OctoPlus into Dr. Reddy’s R&D organization. Prior to OctoPlus, Gerben Moolhuizen worked, among others, at Pharming, where he held various roles in business development and product development and was also involved in the company´s IPO in 1998 . He holds an M.Sc. from Utrecht University in Medical Biology and an MBA from Erasmus University Rotterdam.

Cornelis Melief, Ph.D.
Cornelis Melief, Ph.D., Chief Scientific Officer

Cornelis Melief has made significant contributions to the field of immunology, in particular cancer immunology. In 1991, he became professor at the LUMC and since then his group has been working intensively to devise new cancer therapies based on the activation of the patient’s own immune system. Before, he headed the immunology department at the Netherlands Cancer Institute (NKI). He started his career at the blood bank in Amsterdam (CLB). Cornelis is member of the Royal Netherlands Academy of Arts and Sciences. He is author of more than 450 peer-reviewed publications and inventor on more than 30 patents and patent applications.

Willem-Jan Krebber
Willem-Jan Krebber, Chief Operating Officer

Willem-Jan Krebber has over 15 years of experience in the pharmaceutical and biotechnology industry in various roles covering process development, manufacturing and project management. In his current role as Chief Operating Officer he leads all innovation, product development and manufacturing activities within the company. Prior to ISA Pharmaceuticals, he worked at OctoPlus (now Dr. Reddy’s R&D) as CMC Program Manager where he was responsible for managing OctoPlus own product and technology development programs on advanced drug formulations and delivery. Prior to OctoPlus he held various CMC and project management positions at Crucell (now part of Janssen Vaccines & Prevention and Johnson & Johnson) for the development and manufacturing of cell-based products. Willem-Jan Krebber holds a Masters in Biology from Utrecht University and a Masters in Biotechnology from Delft University of Technology.

Dr. Leon Hooftman, Chief Medical Officer

Dr. Leon Hooftman is an experienced clinician and has initiated and successfully completed numerous clinical studies in immunology, oncology and immuno-oncology. Before joining ISA Pharmaceuticals in May 2018, he worked at Allecra Therapeutics Ltd, where he oversaw the clinical development of a novel antibiotic agent. Prior to this, he held CMO positions in several biotech companies – amongst others, Polyphor AG and Chroma Therapeutics. Previously, he was Head of Clinical Development at Celltech Group Plc until the company was acquired by UCB. Before moving into biotechnology, Leon worked at F. Hoffmann La Roche for more than 8 years where he was Director of Clinical Science, Oncology and Immunology. At Roche – amongst other projects – he led the clinical team that successfully completed a registration study with rituximab in first line NHL which gave the antibody approval in a first-line cancer indication. Prior to that, he was the lead MD of the group that achieved approval of 2 novel immunosuppressant agents, initially at Syntex, which was acquired by Roche. Dr. Hooftman is also an accomplished scientist and author of more than 50 scientific papers and publications.